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Abstract 
Introduction: Few data have been published comparing early‑phase trials for lung cancer between China and the 
United States (US). This study was to investigate the differences of phase 1 trials for lung cancer between these two 
countries.
Methods: In 2014, a cross‑sectional survey was conducted to compare phase 1 trials for lung cancer between the 
Guangdong Lung Cancer Institute (GLCI), the University of Wisconsin Carbone Cancer Center (UWCCC), and the Uni‑
versity of Texas MD Anderson Cancer Center (MDACC).
Results: We found that the GLCI had a lower percentage of phase 1 lung cancer trials than the MDACC in December 
2014 (23.8% [5/21] vs. 59.8% [28/47], P = 0.006) and the UWCCC in September 2014 (16.7% [3/18] vs. 34.8% [8/23], 
P = 0.345). Descriptive analyses were performed for early‑phase trials conducted by the Cancer Therapy Evaluation 
Program at the National Cancer Institute (CTEP/NCI), the MDACC, and the Chinese Thoracic Oncology Group (CTONG). 
There were 149 ongoing early‑phase trials in the Department of Investigational Cancer Therapeutics (Phase 1 pro‑
gram) at the MDACC in October 2014. In contrast, no phase 1 trials had been initiated by the CTONG since its estab‑
lishment in 2007.
Conclusions: These data suggest that a significantly higher percentage of phase 1 trials for lung cancer were con‑
ducted in the US than in China. Early‑phase oncology trials with robust preclinical data had a higher chance of being 
approved by the Investigational Drug Branch at the CTEP/NCI. Given the importance of early‑phase oncology trials in 
developing innovative cancer medicines, such studies should be highly encouraged and strategically funded in China.
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Non-small cell lung cancer (NSCLC) accounts for 
approximately 80% of primary lung cancer, which is 
the leading cause of cancer-related death in both men 
and women worldwide. More than one half (55%) of 
NSCLC patients with metastatic disease are medically 
and surgically incurable [1], leading to a poor progno-
sis with a median survival of 8–9  months [2, 3]. There-
fore, more and more clinical trials have been designed to 
treat patients with advanced NSCLC. The Iressa NSCLC 
Trial Evaluating Response and Survival Versus Taxotere 
(INTEREST) trial [4], a global, multi-center, randomized, 
phase 3 trial conducted in 2004, was the starting point at 
which Chinese investigators contributed to making lung 
cancer history. Over the past decade, Chinese investi-
gators have completed several phase 3 trials [5–8] that 
have greatly changed the clinical practice of treating lung 
cancer [9], including the Iressa Pan-Asia Study (IPASS), 
which was a milestone trial [5]. The Chinese Thoracic 
Oncology Group (CTONG) has launched more than 
30 trials since its establishment in 2007. However, most 
of the ongoing trials for lung cancer at the CTONG are 
observational phase 2 and 3 studies [10]. Since its incep-
tion, the CTONG has yet to conduct any early-phase tri-
als for lung cancer, particularly phase 1 trials.
Phase 1 studies of novel anticancer agents are a cru-
cial step in antitumor drug development, as they trans-
late years of bench studies to the bedside. The primary 
goal of phase 1 trials is to establish a safe and reliable 
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recommended dose and schedule for upcoming phase 2 
and 3 testing. In the era of molecularly targeted therapy, 
phase 1 trials have been conducted not only to achieve 
this primary goal but also to identify specific target 
patient populations and produce preliminary biomarker 
evidence of targeted therapy [11]. The most amazing 
example was the anaplastic lymphoma kinase (ALK) 
story, in which the oral c-mesenchymal-epithelial transi-
tion (c-MET) and ALK inhibitor crizotinib was approved 
for patients with NSCLC harboring the echinoderm 
microtubule-associated protein-like 4 (EML4)-ALK rear-
rangement by the United States (US) Food and Drug 
Administration (FDA) in August 2011 and by the Euro-
pean Medicine Agency in Autumn 2012; this occurred 
just after an expansion of a phase 1 trial was success-
fully published in 2010 [12], although the EML4-ALK 
rearrangement in NSCLC was discovered in 2007 [13]. 
Other examples of phase 1 trials that have successfully 
been enriched for specific target patient populations 
include the hedgehog inhibitor GDC-0449 in patients 
with advanced basal cell carcinoma [14, 15] and the 
v-Raf murine sarcoma viral oncogene homolog B (BRAF) 
inhibitor PLX4032 in patients with malignant melanoma 
harboring V600E BRAF mutations [16]. Additionally, 
phase 1 trials enrolling patients based on genomic anal-
yses have a higher probability of showing efficacy than 
those with patients who are not genetically selected [17]. 
Globally, several institutes have applied next-generation 
sequencing techniques to the phase 1 setting for person-
alized oncology [18].
In the background of the rapidly evolving clinical trial 
system mentioned above, Dr. Jin-Ji Yang, an experienced 
investigator focusing on lung cancer at Guangdong 
Lung Cancer Institute (GLCI) in China, participated in 
a 4-month intensive training (September to December 
2014) in the US in early-phase oncology trials sponsored 
by the Hengrui-US Chinese Anti-Cancer Association 
(USCACA) Scholarship for Early Phase Oncology Drug 
Development. By this chance, we performed a cross-
sectional survey of early-phase oncology trials, particu-
larly phase 1 studies of lung cancer, between the US and 
China.
Materials and methods
Brief introduction of cancer institutes visited by Dr. Yang 
in the US
Dr. Yang was an observer at the University of Wisconsin 
Carbone Cancer Center (UWCCC) in September and 
the University of Texas MD Anderson Cancer Center 
(MDACC) in December, 2014. He was a visiting fel-
low at the Cancer Therapy Evaluation Program at the 
National Cancer Institute (CTEP/NCI) in October and 
November, 2014. The GLCI is the largest leading lung 
cancer research facility in China [19]. Meanwhile, the 
MDACC and UWCCC are top cancer institutes in the 
US, particularly for high-quality early-phase oncology 
trials. A cross-sectional survey of early-phase trials for 
lung cancer was conducted between the UWCCC and 
GLCI in September, as well as between the MDACC 
and GLCI in December. Meanwhile, in addition to the 
MDACC, descriptive analyses of early-phase oncol-
ogy trials were performed at both the CTEP/NCI and 
CTONG.
Working system of lung cancer at the GLCI, MDACC, 
and UWCCC
The infrastructure and protocols underlying routine 
clinical practice and clinical trials for lung cancer were 
compared among the GLCI, MDACC, and UWCCC, 
including the names of departments, lung cancer doc-
tors, multidisciplinary conferences, multidisciplinary 
clinics, grand rounds, molecular tumor boards, lung can-
cer working group meetings, regular academic discus-
sions, and protocol review and monitoring committee 
(PRMC) meetings.
Ongoing clinical trials for lung cancer at the GLCI, MDACC, 
and UWCCC
An ongoing clinical trial for lung cancer was defined 
as a trial specifically focusing on lung cancer and not 
including other solid tumors or malignancies that had 
been approved by the Institutional Review Board (IRB)/
Independent Ethics Committee (IEC) and was open for 
recruiting subjects. Ongoing trials for lung cancer were 
classified into four types: phase 1, phase 2, phase 3, and 
others. Phase 1 included pure phase 1 and phase 1/2 tri-
als. Phase 2 comprised pure phase 2 and phase 2/3 trials. 
Observational studies, surveys, laboratory analyses, and 
unclassified trials were defined as “others”. Phase 4 trials 
were excluded.
Ongoing early‑phase oncology trials at the MDACC
The Department of Investigational Cancer Therapeutics 
(ICT) focuses solely on early-phase oncology trials at the 
MDACC, mainly including phase 1 and 2 trials, which 
accounted for approximately 70 and 30% of all trials, 
respectively. Although Dr. Yang visited this department 
in December 2014, data were available on early-phase 
oncology trials for the period of October 2014.
Early‑phase oncology trials reviewed by the Investigational 
Drug Branch (IDB) at the CTEP/NCI
Early-phase oncology trials included phase 1, phase 
1/2, phase 2, and “pilot” studies reviewed by the IDB in 
October and November 2014. A pilot study is an early 
trial that does not fit in as a traditional phase 1 or 2 trial. 
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Those trials often incorporate biomarker assays that were 
categorized into 3 types: integral, integrated, or explora-
tory. For an integral type assay, the result is required for 
patient enrollment, or the assay is required to assess a 
primary objective. For an integrated type assay, the result 
addresses a study hypothesis or is measured to support 
an objective. Notably, some assays proposed in second-
ary objectives may actually be exploratory. In making this 
distinction, it may be helpful to consider how likely it is 
that the assay might be required as an integral marker in 
the next trial. An exploratory type assay is neither inte-
gral nor integrated. Data for such a biomarker assay may 
help to generate a new therapy hypothesis that might be 
tested in future clinical trials, but the assay is optional in 
the current study.
For the purpose of this article, preclinical data may 
be considered “robust” or “non-robust.” Robust pre-
clinical data must include all the following: (1) in vitro 
anti-tumor activity of at least two different cell lines; (2) 
in vivo anti-tumor efficacy of at least two tumor types; 
and (3) evidence of the effect on the drug target in in 
vivo tumor models at doses that are plausibly achiev-
able in humans [20]. Otherwise, the data are considered 
non-robust.
Proposals for early clinical trials to be sponsored by 
the NCI were reviewed by a panel of senior investigators 
at the IDB-CTEP/NCI. The outcome of the review was 
either “approved” or “disapproved.”
Clinical trials for lung cancer launched by the CTONG
Since 2008, all CTONG trials for lung cancer were cate-
gorized as (neo)adjuvant epidermal growth factor recep-
tor tyrosine kinase inhibitors (EGFR TKIs), intercalating/
maintenance EGFR TKIs, first-line, second/third-line, 
and observational, in addition to the classifications of 
phases mentioned above.
Outcome assessment
The percentage of phase 1 trials for lung cancer was com-
pared among the GLCI, MDACC, and UWCCC. Gen-
eral descriptive analyses were performed for the working 
system of lung cancer teams among the GLCI, MDACC, 
and UWCCC, for the early-phase oncology trials at the 
MDACC and CTEP/NCI, and for CTONG lung cancer 
trials.
Statistical analysis
The percentage of phase 1 trials for lung cancer and the 
approved rate of early-phase oncology trials were ana-
lyzed by the χ2 test (two-sided). The difference was con-
sidered significant at P  <  0.05. Statistical computations 
were performed with SPSS version 13.0 (SPSS Inc., Chi-
cago, IL, USA).
Results
Description of the working system of lung cancer teams 
at the GLCI, MDACC, and UWCCC
The infrastructure and protocols of routine clinical prac-
tice and clinical trials for lung cancer among the 3 insti-
tutes are summarized in Table 1. In general, the running 
mechanism was approximately the same, although the 
UWCCC appeared to have a relatively complete system. 
However, the lung cancer team, named the Department 
of Pulmonary Oncology, comprised medical, surgical, 
and radiation oncologists at the GLCI, whereas only 
medical oncologists comprised the Department of Tho-
racic Head and Neck Medical Oncology at both the 
MDACC and UWCCC. The latter two institutes held 
regular PRMC meetings. At the GLCI, such meetings are 
replaced by a series of monthly meetings for academic 
discussions.
Comparing the percentage of phase 1 trials for lung cancer 
among the GLCI, MDACC, and UWCCC
The GLCI had a significantly lower percentage of phase 1 
trials than the MDACC in December 2014 (23.8% [5/21] 
vs. 59.8% [28/47], χ2 = 7.433, P = 0.006), but there was 
no significant difference between the GLCI and UWCCC 
in September 2014 (16.7% [3/18] vs. 34.8% [8/23], 
χ2 = 0.891, P = 0.345) (Table 1).
Description of ongoing early‑phase oncology trials at the 
MDACC
Data on early-phase oncology trials at the MDACC in 
October 2014 are shown in Figure 1. Among 149 ongoing 
early-phase trials, first-in-human studies accounted for 
29%, and all phase 1 trials that were not first-in-human 
studies accounted for 23%. There were no overlapping 
trials between the Department of ICT and the Depart-
ment of Thoracic Head and Neck Medical Oncology.
The approval rate of early‑phase oncology trials with and 
without robust preclinical data at the IDB‑CTEP/NCI
The CTEP/NCI organizational chart is shown in Fig-
ure  2. Commonly observed solid tumors and hemato-
logic malignancies were included in reviewed early-phase 
oncology trials. All investigational drugs and combina-
tions had well defined targets, and biomarker identi-
fication was required in all trials. The approval rate of 
early-phase trials with robust preclinical data was gener-
ally higher than that of those without robust preclinical 
data.
General description of clinical trials for lung cancer 
launched by the CTONG
The CTONG was established in 2007 and launched its 
first trial for lung cancer in 2008. A total of 26 clinical 
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trials for lung cancer have been initiated by the CTONG 
up until December 2014. Among them, phase 2, 2/3, 3, 
and others accounted for 38% (10/26), 12% (3/26), 35% 
(9/26), and 15% (4/26), respectively (Figure 3a). However, 
no single phase 1 trials were conducted. (Neo)adjuvant 
EGFR TKIs, intercalating/maintenance EGFR TKIs, 
first-line, second/third-line, and observational trials 
accounted for 15% (4/26), 12% (3/26), 46% (12/26), 12% 
(3/26), and 15% (4/26), respectively (Figure 3b).
Discussion
To the best of our knowledge, this is the first cross-
sectional survey of early-phase trials for lung cancer 
between China and the US. A significantly higher per-
centage of phase 1 lung cancer trials was found in the US 
than in China. Moreover, the early-phase oncology tri-
als were highly strengthened at both the NCI and cancer 
centers in the US.
In general, the GLCI, MDACC, and UWCCC share a 
similar working system of lung cancer teams with multi-
disciplinary modalities for treating lung cancer patients. 
Globally, multidisciplinary teams (MDTs) have resulted 
in better clinical care outcomes for cancer patients, with 
evidence of prolonged survival among patients with 
a variety of solid tumors, including lung cancer [21]. 
Medical, surgical, and radiation oncologists comprise 
the Department of Pulmonary Oncology at the GLCI, 
Table 1 Comparison of the working system for lung cancer trials among 3 institutes
GLCI Guangdong Lung Cancer Institute, MDACC MD Anderson Cancer Center, UWCCC University of Wisconsin Carbone Cancer Center, PRMC protocol review and moni-
toring committee.
a Grand Round refers to an academic lecture formally given by a specialist, expert, professor, scientist, or occasionally, a PhD student who is within a hospital/insti-
tute/university or from outside.
Item GLCI MDACC UWCCC
Department Pulmonary Oncology Thoracic Head and Neck Medical 
Oncology
Thoracic Head and Neck Medical 
Oncology
Physicians Medical, surgical, and radiation 
oncologists
Medical oncologists Medical oncologists
Multidisciplinary clinic No No Yes
Multidisciplinary conference Yes Yes Yes
Grand roundsa No Yes Yes
Working group meeting for trials Every 2–3 weeks Weekly Weekly
PRMC meeting No Yes, monthly Yes, biweekly
Molecular tumor board or discussion 
and strategies for incorporation of 
molecular characteristics
No No Yes
Academic discussion about transla‑
tional medicine of lung cancer
Monthly No No
Clinical trials in September 2014 Not available
 Phase 1 3 8
 Phase 2 4 8
 Phase 3 4 4
 Others 7 3
Clinical trials in December 2014 Not available
 Phase 1 5 28
 Phase 2 5 15
 Phase 3 4 3
 Others 7 1
Figure 1 Early‑phase oncology trials at the Department of Investi‑
gational Cancer Therapeutics at MD Anderson Cancer Center. Comm 
commercial, Exp experimental.
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resulting in more coordinated and efficient MDTs. How-
ever, no PRMC meetings occurred at the GLCI. PRMC 
meetings play an important role in clinical trial develop-
ment and regulation [22]. It is strongly recommended 
that PRMC meetings be held at the GLCI as well as at 
large cancer institutes in China.
In December 2014, the GLCI had a significantly 
lower percentage of phase 1 lung cancer trials than the 
MDACC, although the percentage is similar to that at 
the UWCCC in September 2014. No phase 1 lung can-
cer trials were ever launched at the CTONG. Moreover, 
an entire department of the ICT was dedicated to early-
phase oncology trials at the MDACC, which was thought 
to be the first phase 1 clinical trial program in the world. 
Over the last 5  years, the MDACC ICT conducted 
phase 1 first-in-human trials for 4 novel targeted agents 
approved by the US FDA: dabrafenib (GSK2118436) [23], 
trametinib (GSK1120212) [24], cabozantinib (XL184) 
[25], and siltuximab (CNTO328) [26]. This showcases the 
MDACC as the pioneer of innovative anti-cancer drug 
development not only in the US but also worldwide. In 
the era of molecularly targeted therapy, phase 1 trials 
based on biomarkers and cancer genomics have played 
a significant role in drug development and are critical 
to the translation of preclinical success to the practice 
of oncology [11–18]. To keep pace with the innovation 
of anti-cancer drugs globally, more early-phase, particu-
larly phase 1, trials should be encouraged at the GLCI, 
CTONG, and other caner institutes in China.
As observed in the CTEP/NCI review process of early 
clinical trial proposals, robust preclinical data gener-
ally provide strong rationale and are considered to be of 
high priority for clinical evaluation. It is challenging to 
make appropriate decisions regarding moving new can-
cer agents from late preclinical development into phase 
1 and from phase 1 into phase 2 trials. Among preclini-
cal data, the extent of in vivo anti-tumor efficacy required 
to support the clinical development of innovative drugs 
Figure 2 Branches of the Cancer Therapy Evaluation Program (CTEP) at the National Cancer Institute (NCI) in the United States.
Figure 3 Distributions of trials for lung cancer initiated by the Chinese Thoracic Oncology Group (CTONG). a by phases of trials, b by treatments. 
EGFR TKIs Epidermal growth factor receptor tyrosine kinase inhibitors.
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remains controversial [20]. Importantly, the availability of 
biomarkers and biomarker assays is critical to consider in 
planning the approach to phase 1 clinical trials [11]. Most 
of the trials reviewed by the IDB have at least some degree 
of biomarker involvement, which also requires stringent 
reviews with regard to the roles of biomarkers in the trial 
and the analytical performances of the biomarker assays. 
In China, few innovative targeted anti-cancer agents for 
lung cancer have been successfully developed, except for 
icotinib, which is an EGFR TKI approved for advanced 
NSCLC by the China FDA (CFDA) [8]. Therefore, robust 
preclinical data and appropriate biomarker assays should 
be prioritized in the design of phase 1 trials.
The mission of the CTEP is to improve the lives of can-
cer patients by finding better ways to treat, control, and 
cure cancer. The CTEP accomplishes this mission by 
funding an extensive national program of cancer research 
and by sponsoring clinical trials to evaluate new anti-
cancer agents, with a particular emphasis on translational 
research to elucidate molecular targets and the mecha-
nisms of drug effects. As far as we know, no institution 
similar to the CTEP exists in China. Without government 
funding or sponsorship, some promising early-phase 
oncology trials lost the opportunity to be further academ-
ically developed. For example, the CTONG0806 study, 
a multi-center phase 2 trial, was initiated to explore the 
efficacy and tolerability of pemetrexed versus gefitinib as 
a second-line treatment in patients with advanced non-
squamous NSCLC harboring wild-type EGFR [27]. The 
lack of funding or sponsorship led to slower accrual and 
much more delayed publication of CTONG0806 than 
two other similar trials [28, 29]. Thus, we suggest that 
early-phase oncology trials should be funded or spon-
sored by the National Natural Science Funding of China 
(NSFC) and CFDA to facilitate the development of inno-
vative anti-cancer agents in China (Figure 4).
Several limitations exist in this cross-sectional sur-
vey. As an observer or visiting fellow, Dr. Yang was not 
authorized to obtain sufficient data directly from the 
UWCCC, CTEP/NCI, and MDACC, all of which with-
held some data due to academic confidentiality. There-
fore, the data for analysis were incomplete. Finally, none 
of the staff from the CTEP/NCI, MDACC, and UWCCC 
were directly involved in authoring this study.
In conclusion, institutes in China and the US share a 
similar working system of lung cancer teams for routine 
clinical practice and clinical trials. A higher percentage of 
phase 1 trials for lung cancer was observed in the US than 
in China. The early-phase oncology trials with robust 
preclinical data had a higher chance of being approved 
by the IDB at the CTEP/NCI. Significantly more early-
phase oncology trials were conducted in the US. Early-
phase oncology trials should be encouraged and funded 
in China.
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